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Background: Tuberous Sclerosis Complex (TSC) is a genetic disorder characterised by the development of
benign tumours secondary to loss of inhibitory regulation of the mTOR (mechanistic Target of Rapamycin)
intracellular growth pathway. Metformin inhibits the mTOR pathway. We investigated whether metformin
would reduce growth of hamartomas associated with tuberous sclerosis complex.
Methods: In this multicentre randomized, double-blind, placebo-controlled trial, patients with a clinical
diagnosis of tuberous sclerosis, aged over 10 years and with at least one renal angiomyolipoma of greater
than 1 cm in diameter were enrolled. Participants were randomly allocated (1:1) by a secure website to
receive metformin or placebo for 12 months. The primary outcome was percentage volume change of
renal angiomyolipomas (AML) at 12 months compared to baseline. Secondary outcomes were percentage
change at 12 months from baseline in volume of cerebral Subependymal Giant Cell Astrocytomas (SEGA);
appearance of facial and ungual hamartomas; frequency of epileptic seizures; and adaptive behaviour.
The trial is registered with The International Standard Randomised Controlled Trial Number (ISRCTN),
number 92545532, and the European Union Drug Regulating Authorities Clinical Trials (EUDRACT), num-
ber 2011-001319-30.
Findings: Between 1 November 2012 and 30 September 2015 72 patients were screened and 55 were ran-
domly assigned to metformin (28) or placebo (27). Four participants withdrew between randomisation and
starting treatment. All 51 patients who started therapy completed the trial and were assessed for outcome at
12 months. The median percentage change in angiomyolipoma (AML) volume was +7.6% (IQR -1.8% to
+42.6%) for the placebo group and +8.9% (IQR 1.3% to 19.5%) for the metformin group (p = 0.28). Twenty-
seven patients had SEGAs: 13 received placebo and 14 metformin. The median percentage change in SEGA
volume was +3.0% (IQR -22.8% to +27.7%) for the placebo group and  20.8% (IQR  47.1% to - 5.0%) for the
metformin group (p = 0.03). Twenty-one patients were assessed for seizure frequency: 9 received placebo
and 12 received metformin. In the metformin group, a mean reduction of 43.7% from baseline in seizures
was observed and in the placebo group a 3.1% mean reduction was observed, with a difference in response of
40.6% (95% CI -3.1% to +84.2%, p = 0.03). There were no significant differences between metformin and pla-
cebo groups for the other secondary outcomes. There were no deaths. Three serious adverse events (SAEs)
occurred during the trial (all patients on metformin).
Interpretation: Metformin did not reduce AML volume. Metformin did reduce SEGA volume and seizure fre-
quency compared with placebo. There may be a role for metformin in slowing or reversing growth of some
life-threatening hamartomas in TSC and for reducing seizure frequency. Further study is justified.tion, Room 41, 4th Floor PUW South, Institute of Child Health, University College London, London WC1N 1EH, United King-
han).
d. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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indicated.1. Introduction
Tuberous Sclerosis Complex (TSC) is a relatively common genetic
disorder with a prevalence between 4 and 9 per 100,000. [1]. Based
on the revised diagnostic criteria the estimated incidence rate of defi-
nite or possible TSC is between 1 in 6760 and 1 in 13,520 live births
[2]. It is characterized by the development of tumours (hamartomas)
throughout the body. Tumours affecting the heart (cardiac rhabdo-
myomas), kidneys (renal angiomyolipomas) and brain (subependy-
mal giant cell astrocytomas) can cause life threatening complications
[1]. Tumours on the skin and nails can be significantly disfiguring.
TSC is associated with epilepsy in approximately 75% of patients and
with learning difficulties in approximately 50%. Individuals with TSCmay also have a range of psychological and behavioural problems
including autism [3]. Many adults with TSC are unable to live inde-
pendently and require state or family care [4].
TSC is caused by mutations in the tumour suppressor genes TSC1
on chromosome 9 or TSC2 on chromosome 16 that encode for the
proteins hamartin and tuberin respectively [5, 6]. Hamartin and
tuberin function together within the cell as a complex, and have an
inhibitory effect on the mechanistic Target Of Rapamycin (mTOR), a
protein kinase that effects cell growth and division through the regu-
lation of protein synthesis [7]. Mutations in either the TSC1 or TSC2
genes allows over-activation of the mTOR pathway, which leads to
relatively uncontrolled cell growth and, in turn, the formation of
hamartomas in multiple organs.
Recent studies have shown that drugs that inhibit mTOR, specifi-
cally rapamycin and everolimus, can reduce TSC-related lesions such
as renal angiomyolipomas (AMLs), Subependymal Giant Cell Astrocy-
tomas (SEGAs) and facial angiofibromas in humans [8]. Spontaneous
regression of these hamartomas is not commonly seen [9]. Rapamy-
cin has been shown to reverse learning deficits and improve epilepsy
in mouse models of TSC [10]. The EXIST-3 trial has shown that evero-
limus therapy reduces seizure frequency in patients with TSC and
treatment-resistant focal seizures and that it has a tolerable safety
profile [11]. Rapamycin and everolimus have a relatively high inci-
dence of adverse events such as mucositis, diarrhoea, and respiratory
infections severe enough to require hospitalization in a third of
patients [12]. Everolimus treatment in TSC patients has also rarely
been associated with life-threatening outcomes, including sepsis and
death [13]. Patients sometimes require periods off therapy and this
interruption has been linked to the re-growth of tumours [8]. Little is
known about the long-term (> 5 years) side effects of these drugs.
Metformin inhibits the mTOR pathway via activation of adenosine
monophosphate-activated protein kinase (AMPK) and p53 [14, 15]. It
has been used for over 50 years to aid glycaemic control in patients
with type 2 diabetes, and has a benign side effect profile [16]. It does
not lower blood sugar in non-diabetic people unless given in over-
dose [16]. We hypothesised that metformin will reduce TSC-related
tumour size via the inhibition of mTOR. We also hypothesized that
metformin may improve epilepsy and cognitive ability in patients
with TSC. Therefore, we conducted a clinical experiment using met-
formin in the form of a randomised double-blinded placebo-con-
trolled trial in patients with TSC.2. Methods
2.1. Study design
The Metformin in Tuberous Sclerosis (MiTS) study was a rando-
mised double-blind placebo-controlled trial. Three hospitals with
specialist TSC services enrolled patients (Royal United Hospital [41
patients], Great Ormond Street Hospital [3 patients], and Bristol Royal
Hospital for Sick Children [11 patients]). These are three TS clinics run
by the study group. These clinics follow up the largest number of TSC
patients in the UK. Prior to their standard clinic appointment, all
clinic patients (or their parents/carers) were sent a letter introducing
the study (including participant information sheets and study team
contact details). They were offered the opportunity to discuss the
study at an appointment directly after their next clinic visit.
Investigators (SA, and FO’C) who worked at all three sites, enrolled
and managed patients in the trial. Treatment allocation was
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tion Unit, School of Social and Community Medicine, University of
Bristol. Our research protocol was approved by the UK Yorkshire and
Humber Multicentre Research Ethics Committee (11/YH/0295) and
all relevant local research ethics committees. The full protocol is
available at https://bristolcns.org/research/
2.2. Participants
Inclusion criteria were a clinical diagnosis of tuberous sclerosis
complex as defined by the International Tuberous Sclerosis Complex
Consensus Group [17, 18], age 10 to 65 years, and the presence of at
least one renal angiomyolipoma of  one centimetre in diameter.
Exclusion criteria were: a serious inter-current illness or an uncon-
trolled disease that could compromise participation in the study, pre-
existing impairment of renal function, the use of x-ray contrast
medium containing iodine within the last 30 days, multiple AMLs
that cannot be distinguished separately on magnetic resonance imag-
ing (MRI), renal haemorrhage within the preceding 12 months, pres-
ence of renal aneurysms > 10 mm in diameter, impaired liver
function, acute or chronic disease which may cause tissue hypoxia
and increase the risk of lactic acidosis (e.g. cardiac/respiratory failure,
recent myocardial infarction), pre-existing diabetes, current treat-
ment with injected or oral hypoglycaemic drugs, pregnancy, planning
to become pregnant, or breastfeeding.
2.3. Randomisation and masking
Patients were randomly allocated (1:1) to placebo or metformin
for 12 months. The randomisation was stratified by centre and mini-
mised by age-group (10 to <20; 20 to <30; 30 to <40; and 40 to
<65) and by the presence or absence of learning disabilities. The ran-
domisation was concealed from investigators. The investigators rand-
omised patients online and received a randomisation number and
treatment pack number that they then wrote on the study prescrip-
tion form. The prescriptions were sent to the main trial pharmacy at
the sponsor’s site. On receipt of the prescription forms, the Trial phar-
macists identified the treatment pack number on their (provided)
spreadsheet that listed the drug to dispense for each treatment pack
number. The online randomisation system sent an automatic email
to all pharmacists confirming the recruited patient’s ID, centre and
drug allocation. The pharmacists made up the treatment pack and
dispensed the trial treatment. The online randomisation was per-
formed by the (BRTC) Bristol Randomised Trials Collaboration Unit,
School of Social and Community Medicine, University of Bristol.
2.4. Procedures
The study treatments were metformin (standard 500 mg tablets,
manufactured by Relonchem Ltd, Widnes, Cheshire) and placebo
(500 mg tablets, manufactured by Essential Nutrition Ltd, Brough,
UK). Metformin and placebo tablets were matched for shape, size and
colour. Both were labelled, and final quantitative pharmacology
release was certified by the University Hospitals Bristol Pharmaceuti-
cals.
For adult patients (> 16 years), the starting dose was 500 mg
twice a day orally. At 6 months, the dose was escalated to 500 mg
three times if the patient was tolerating the treatment. For children
aged 1016 years, the drug dosing started at 500 mg once a day.
After two weeks the dose was escalated to 500 mg twice a day. At 6
months the dose was escalated to 500 mg three times a day if the
patient was tolerating treatment.
All patients had a renal MRI at baseline prior to initiation of treat-
ment and 12 months after starting the treatment. Patients with learn-
ing disabilities, and some of the children, required general
anaesthetic for the MRI. The same MRI protocol was used in the threecentres. MRI (1.5 tesla) was used with gadolinium intravenous con-
trast agent. Fat saturated spoiled gradient echo sequences were per-
formed in axial and coronal planes. Contrast bolus was adjusted by
body weight according to manufacturer dose specifications. The scans
were analysed by a radiologist (MLa) who was blind to treatment
allocation. Images were reviewed on a work-station (Fuji Synapse
PACS, Fujifilm, Japan). Lesions were measured in three dimensions
with baseline AMLs required to measure at least 1 cm in diameter.
The volume measurements were performed as an approximated
ellipsoid using the formula, width £ depth £ length x 0.523. The vol-
ume of up to the five largest AMLs per patient were identified from
the baseline and 12-month scans. The five largest lesions were cho-
sen in those patients who had more than five lesions measuring 
1 cm. The mean volume of all the measured lesions was calculated
for each patient at baseline and 12 months.
Each patient in the trial also had a baseline cranial MRI and a fol-
low-up cranial MRI 12 months after the initiation of treatment. Up to
2 SEGAs were identified per patient. The two largest SEGA lesions
were chosen in patients who had more than two SEGA lesions. SEGA
was defined as a lesion at the Foramen of Monro which enhances
with contrast, and measures  0.5 cm in diameter. The volume of
SEGAs was calculated at the baseline and 12-month scan. The scans
were analysed by a neuroradiologist (MLi) who was blind to treat-
ment allocation. Identical volumetric measurement methodology
was used as for the AML lesions.
The facial angiofibromas and ungual fibromas were assessed at
baseline and at 12 months after initiation of treatment using digital
photography. These lesions were assessed objectively by a derma-
tologist blinded to treatment allocation using physician’s global
assessment (PGA) [19] of digital photographs and subjectively by
patient/parent/carer report after 12 months of treatment. The PGA
has a seven-point scale ranging from a score of 0 (no evidence of
disease / 100% improvement) to 6 (Disease is worse than at baseline
> 25% or more). Consequently, a lower score on the PGA indicates
greater improvement. The same 10.2 mega pixels digital camera
was used for all the patients, in all the three centres, by the same
researcher (SA). Six photographs were taken from each patient at
baseline and at the 12-month visit. Three photographs were taken
with the camera flash on and the other three are taken with the
flash in automatic mode. One photograph was taken in full-face
view directly facing the camera and the other two were side pro-
files. Patients were advised not to wear makeup before having their
photograph taken.
Patients or their caregivers recorded seizure events in a seizure
diary for one month prior to initiating treatment and for one month
prior to the 12-month assessment. Adaptive behaviour outcome was
measured using the Vineland Adaptive Behaviour Scales (VABS) [20]
Composite Score. The Vineland is a validated measure of adaptive
behaviour that yields an age standardised score with a population
mean of 100 and a standard deviation of 15. The Vineland was
administered at baseline and 12 months in face-to-face interviews by
the researcher (SA) who was blinded to treatment allocation. Health
related Quality of Life (QOL) was assessed at baseline and at 12
months using the paediatric Quality of Life Inventory (PedsQL) for
children (ages 10 to18 years), and the Short Form 36 Health Survey
(SF-36) for adults without learning difficulty (i.e. > 18 years).
Consent was obtained from the parents or legal guardians of chil-
dren. Assent from the children was also sought were possible. Con-
sent was obtained from adults with normal intellect. Parents cannot
give consent on behalf of their children once they are over 18, even if
they have learning disabilities. For this group of patients, consent
was obtained from all the parties who were involved in the patients’
care such as parents, guardians, carers, legal representatives, general
practitioners, case workers, support workers and hospital specialists,
via best interest decision. The investigators communicated with these
parties by email, phone, or face to face meetings, to explain the study
4 S. Amin et al. / EClinicalMedicine 32 (2021) 100715and obtain written consent from them. This was in line with ethical
approval.
2.5. Pharmacovigilance
Toxicity was graded using the National Cancer Institute's Common
Terminology Criteria for Adverse Events [21]. Participants recorded a
daily diary for the first 14 days, then a monthly diary thereafter. Fol-
lowing any dose escalation there was a further 14 days of daily record
keeping. Clinical assessment including measurement of renal and
liver function and blood glucose levels occurred at baseline, 6 weeks
after starting treatment, and then 6 weeks after any dose change at 6
months.
2.6. Outcomes
The primary outcome was percentage change from baseline in
renal angiomyolipoma (AML) volume measured via magnetic reso-
nance imaging (MRI). Secondary outcomes were percentage change
from baseline in SEGA volume measured by MRI; change in appear-
ance of facial angiofibromatosis and ungual fibromas as measured by
Physician Global Assessment score and by patient report; change
from baseline in the frequency of epileptic seizures as measured in
the one month prior to the 12 month assessment (i.e. in the 12th
month of treatment); change from baseline in Vineland Adaptive
Behaviour Scales (VABS) composite score; and change from baseline
in Peds QL and SF-36 quality of life scores.
2.7. Statistical analysis
Sample size calculations for this study were difficult as there is no
previous evidence, either in the experimental or clinical sphere, of
metformin use in tuberous sclerosis complex that could inform the
investigators of likely effect size. However, at the beginning of the
study it was calculated that 36 patients would be needed in each arm
to achieve a statistical power of 90% to detect a mean reduction in
renal tumour volume of 20% at a significance level of 5%.
All the outcome variables were continuous. Initial comparisons
between the active treatment group and placebo for primary and sec-
ondary outcomes were made with using either t-tests or Wilcoxon-
Mann-Whitney (WMW) tests depending upon whether the data was
normally or non-normally distributed. One-sided alternatives were
used as the study hypothesis was that metformin based upon its
documented action on the mTOR pathway would result in reduction
of hamartoma volume compared to placebo. We tested assumptions
of normality using the Shapiro-Wilk’s test and homogeneity of var-
iances with Bartlett’s test using the statistical programme R, version
3.4.2. All other statistical analyses were done with Stata IC, version
11.2.
The trial is registered with The International Standard Rando-
mised Controlled Trial Number (ISRCTN), number 92545532, and the
European Union Drug Regulating Authorities Clinical Trials
(EUDRACT) number 2011-001319-30
2.8. Role of funding source
The sponsor and funder of the study had no role in study design,
data collection, data analysis, data interpretation, or writing of the
report. The senior authors (FJKO’C, SA, MCB) had full access to all the
anonymised data in the study and had final responsibility for the
decision to submit for publication.
3. Results
Between 1st November 2012 and 30th September 2015 72
patients were assessed for eligibility, of whom 55 met the inclusioncriteria and were randomly assigned (see Fig. 1). 28 were allocated to
metformin therapy and 27 to placebo. Three patients allocated to pla-
cebo and one allocated to metformin did not start therapy for social
reasons, leaving 27 patients who started metformin therapy and 24
who started on placebo. All the patients who began treatment com-
pleted the 12-month treatment period and therefore 51 patients
were analysed for primary and secondary outcomes.
The demographic details of the participating cohort are shown in
Table 1. There were no clinically important differences observed
between treatment groups with regard to baseline characteristics.
Adverse events in the Trial were rare and are shown in Table 2.
There were 3 adverse events recorded on placebo and 11 on metfor-
min. There were 3 serious adverse events on metformin therapy that
necessitated hospitalisation: two cases of haemorrhage from angio-
myolipomas and one case of worsening seizure control. None of the
serious adverse events were judged to be serious adverse reactions
to treatment.
3.1. Renal angiomyolipomas
All the patients in the trial had at least one angiomyolipoma  one
centimetre in diameter. The distribution of the percentage volume
changes in participants of the trial on both metformin and placebo is
shown in Fig. 2 and the individual responses to treatment are
depicted in the waterfall plots in Fig. 3. The median percentage
change in AML volume was +7.6% (IQR 1.8% to +42.6%) for the pla-
cebo group and +8.9% (IQR 1.3% to 19.5%) for the metformin group
(WMW test, z = 0.59, p = 0.28).
3.2. Subependymal giant cell astrocytomas
Twenty-seven patients in the trial had at least one subependymal
giant cell astrocytoma. 13 were randomised to placebo and 14 were
randomised to metformin. The distribution of the percentage volume
changes in SEGAs in participants of the trial on both metformin and
placebo is shown in Fig. 4 and the individual responses to treatment
are depicted in the waterfall plots in Fig. 5. The data was not normally
distributed and therefore the difference in treatment effect was ana-
lysed using non-parametric statistics. The median percentage change
in SEGA volume was +3.0% (IQR 22.8% to +27.7%) for the placebo
group and 20.8% (IQR 47.1% to 5.0%) for the metformin group
(WMW test, z = 1.89, p = 0.03). On a priori grounds we know that age
is associated with risk of growth of SEGAs. SEGAs are known to grow
in the first three decades of life and then become more quiescent
such that current screening recommendations suggest screening
only in the first three decades of life. In a retrospective analysis we
sub-divided patients with SEGA into those who were either greater
(n = 14) or less than (n = 13) 30 years of age in order to see whether
metformin was more effective on SEGAs in younger patients, when
lesions are more biologically and clinically active. In patients less
than thirty years, the median percentage change in SEGA volume
was + 11.4% (IQR 22.8% to +162.4%) for the placebo group and 
28.0% (IQR 61.1% to 11.4%) for the metformin group (WMW test,
z = 1.86, p = 0.03). In those patients greater than thirty years, the
median percentage change in SEGA volume was + 3.0% (IQR  39.7%
to + 14.4%) for the placebo group and  10.3% (IQR  49.9%
to + 19.8%) for the metformin group (WMW test, z = 0.70, p = 0.24)
3.3. Epilepsy
Twenty-nine patients had active epilepsy, of whom 14 were on
placebo and 15 on metformin. Eight patients (3 on metformin and 5
on placebo) failed to complete the seizure diary and therefore data
on seizure frequency was available in 21 patients. A mean reduction
of 43.7% from baseline in seizures was observed in the metformin
group and 3.1% in the placebo group, with a difference in response of
Table 1
Baseline patient demographic and disease characteristics.
Metformin (n = 27) Placebo (n = 24)
Median age 30 years 26 years
Age Number of patients (%)
1020 years 9 (33%) 8 (33%)
>2030 years 6 (22%) 6 (25%)
>3040 years 7 (25.9%) 7 (29%)
>4065 years 5 (18.5) 3 (12.5%)
Sex
Men 16 (59%) 9 (37.5%)
Women 11 (40.7%) 15 (62.5%)
Presence of learning disabilities 17 (63%) 17 (70%)
Presence of SEGA 14 (51%) 13 (54%)
Mean diameter angiomyolipoma lesion
8 cm 4 (14.8%) 4 (16.6%)
4 cm and <8 cm 12 (44.4%) 7 (29%)
3 cm and <4 cm 4 (14.8%) 1 (4%)
<3 cm 7 (25.9%) 12 (50%)
Unilateral angiomyolipoma 5 (18.5%) 5 (20.8%)
Number of angiomyolipoma lesions 89 78
Fig. 1. Trial profile.
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Table 2
Shows adverse events in both groups.
Placebo Metformin
Backache (n = 1) Diarrhoea (n = 2)
Dental infection (n = 1) Food poisoning (n = 1)
Headache (n = 1) Fall (n = 1)
Worsening seizures (n = 2)a
Gastric upset (n = 1)
Depression (n = 1)
Urinary Tract Infection (n = 1)
Angiomyolipoma bleeding (n = 2)b
Serious adverse events:.
a 1 admission to hospital.
b 2 patients admitted to hospital.
6 S. Amin et al. / EClinicalMedicine 32 (2021) 10071540.6% (95% CI 3.1% to +84.2%, t = 1.95, p = 0.03). Nine out of twelve
patients on metformin had a reduction in seizure frequency versus
three out of nine patients reporting a reduction in seizure frequency
on placebo. Three patients in the metformin group became seizure
free at the 12-month assessments versus zero patients in the placebo
group becoming seizure-free.
3.4. Facial angiofibromas
Nineteen patients had facial angiofibromas in the placebo group
and 23 in the metformin group. The mean PGA (Physician Global
Assessment) score for facial angiofibroma at 12 months for the pla-
cebo group was 3.4 (95% CI 3.0 to 3.9) and 3.1 (95% CI 2.5 to 3.6) for
the metformin group. A lower score indicates greater improvement
but there was no meaningful difference between the two treatment
groups (t = 1.07, p = 0.3). Two out of 23 patients/carers/parents
reported improvement on metformin. One out of 19 reportedFig. 2. Distribution of percentage volume chaimprovement on placebo. There were no reports of worsening rash in
either group.
3.5. Ungual fibromas
Thirty-eight patients had ungual fibromas, 18 were on placebo
and 20 on metformin. The mean PGA scores at 12 months were 4.4
(95% CI 4.1 to 4.8) for the placebo group and 4.2 (95% CI 3.7 to 4.6) for
the metformin group indicating that there was no clinically meaning-
ful difference between the two groups (t = 1.19, p = 0.24). None of the
patients, carers or parents reported worsening or improving ungual
fibromas in either group.
3.6. Vineland
There was no appreciable change in Vineland scores over the
course of the trial in either treatment group. The total mean adaptive
behaviour scores for the placebo group at baseline was 53.5 (95% CI
38.4 to 68.6), and 54.2 (95% CI 37.4 to 71.0) at 12 months. The total
mean adaptive behaviour scores for the metformin group was 52.7
(95% CI 36.4 to 69.0) at baseline, and 49.5 (95% CI 34.5 to 64.4) at 12
months. The change in adaptive behaviour scores over the 12 months
was + 0.7 (95% CI 3.7 to +5.1) for the placebo group and  3.2 (95%
CI 5.8 to 0.7) for the metformin group (t = 1.7, p = 0.1).
3.7. Quality of life
Health related quality of life was assessed in the trial at baseline
and at 12 months using the paediatric Quality of Life Inventory
(PedsQL) for children (ages 10 to 18 years). The PedsQL can be self-
reported or completed by a proxy (i.e. parent). Self-reported PedsQL
scores were obtained in 6 out of 12 children in the study aged 18nge in AMLs on placebo and metformin.
Fig. 3. (a) Waterfall Plot: AML Volume Change on Metformin. (b) Waterfall Plot: AML Volume Change on Placebo.
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Fig. 4. Distribution of percentage volume changes in SEGAs on placebo and metformin.
8 S. Amin et al. / EClinicalMedicine 32 (2021) 100715years or below. Proxy reported PedsQL scores were obtained in 9 out
of 12 children. Three families failed to return PedsQL forms. The
mean self-reported Peds QL scores for the placebo group at baseline
was 79.9 (95% CI 18.2 to 141.5) and 71.7 (95% CI 10.9 to 154.3) at 12
months. The mean self-reported PedsQL score for the metformin
group at baseline was 76.6 (95% CI 51.3 to 101.9) and 79.0 (95% CI
60.4 to 97.6) at 12 months. The change in self-reported PedsQL scores
over the 12 months was 8.2 (95% CI 152.4 to +136.1) for those
receiving placebo and + 2.4 (95% CI 10.0 to +14.9) for those on met-
formin (t = 1.2, p = 0.3). The mean proxy-reported Peds QL scores for
the placebo group at baseline was 46.6 (95% CI 20.0 to 73.2) and 46.3
(95% CI 14.0 to 78.5) at 12 months. The mean proxy-reported PedsQL
score for the metformin group at baseline was 66.0 (95% CI 39.2 to
92.8) and 72.2 (95% CI 55.9 to 88.6) at 12 months. The change in
proxy-reported PedsQL scores over the 12 months was 0.3 (95% CI
29.7 to +28.9) for those receiving placebo and + 6.2 (95% CI 10.5 to
+23.0) for those on metformin (t = 0.5, p = 0.6).
Health related quality of life in adults was measured using the
Short Form Health Survey (SF-36). The SF-36 is a self-report form and
it was therefore not possible to collect data on the 26 adults with
learning difficulties in the study. SF-36 scores were obtained for 9 out
of 13 adults in the study who did not have learning difficulties. Four
of the adult patients did not return their SF-36 forms. The SF-36 gen-
erates a mental health and physical health summary score. The mean
physical health score for the patients taking placebo at baseline was
39.8 (95% CI 18.3 to 61.3) and 44.8 (95% CI 19.9 to 65.8) at 12 months.
The mean physical health score for the metformin group at baseline
was 61.5 (95% CI 56.2 to 66.8) and 58.3 (95% CI 60.4 to 97.6) at 12
months. The change in physical health scores over the 12 months
was +5 (95% CI 2.9 to +12.9) for those receiving placebo and 3.3
(95% CI 6.8 to +0.3) for those on metformin (t = 2.5, p = 0.04). The
mean SF36 mental health summary score for the placebo group at
baseline was 50.8 (95% CI 39.9 to 61.7) and 45.8 (95% CI 35.5 to 56.1)at 12 months. The mean mental health score for the metformin group
at baseline was 43.3 (95% CI 23.1 to 63.4) and 47.8 (95% CI 40.2 to
55.3) at 12 months. The change in mental health scores over the 12
months was 5 (95% CI 15.0 to +5.0) for those receiving placebo
and +4.5 (95% CI 20.0 to +29.0) for those on metformin (t = 1.2,
p = 0.3).
4. Discussion
This randomised, double-blind, parallel group, placebo-controlled
trial of metformin is the first to investigate the safety and efficacy of
metformin in children and adults with TSC. Metformin was well tol-
erated and did not appear to cause any significant safety issues in
patients during the course of the trial. Metformin did not reduce AML
volume over the course of the trial. However, patients on metformin
had a reduction in SEGA volume compared with placebo and also had
a reduction in epileptic seizure frequency. There was no significant
difference between the treatments with respect to the other second-
ary outcomes. The serious adverse events that occurred during the
trial were apparently unrelated to the trial medication.
There is now an extensive literature describing the beneficial
effects of metformin on a variety of different cancers. [22, 23] The ben-
eficial effect is thought to be mainly due to metformin’s inhibitory
effect on the mechanistic target of rapamycin (mTOR) signalling path-
way via activation of adenosine monophosphate-activated protein
kinase (AMPK). [24] We formulated the hypothesis that treatment
with metformin would result in reduction in size of renal angiomyoli-
pomas in tuberous sclerosis patients. We chose to look at reduction in
volume of angiomyolipomas as our primary outcome because they are
one of the most prevalent hamartomas in TSC, they are associated
with significant morbidity and mortality, [25] and previous trials of
mTOR inhibitors such as rapamycin and everolimus have shown an
effect on these lesions. [12] This trial did not show metformin to have
Fig. 5. (a) Waterfall Plot: SEGA Volume Change on Metformin. (b) Waterfall Plot: SEGA Volume Change on Placebo.
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explanation for this negative result is that metformin simply does not
have a clinically significant inhibitory effect on the mTOR pathway in
TSC patients. Previous studies in a mouse model of TSC did not demon-
strate any therapeutic effect of metformin in reducing the size of renal
cystadenomas that form in this model after loss of expression of the
TSC2 gene. The authors speculate that the complete absence of TSC2 in
the renal cystadenoma lesions in this model leads to strong activation
of mTORC1 due to high levels of RHEB-GTP, which makes the lesions
resistant to the lesser inhibitor effects of metformin. [26] However,
recently Fang et al. reported that metformin treatment effectively pre-
vented aberrant kidney enlargement and cyst growth, inhibited
inflammatory response, attenuated interstitial fibrosis, and protected
renal function in a mouse model of renal proximal tubule-specific
TSC1 gene-knockout. [27]
The effect of metformin on SEGAs seen in this study argues that
metformin may indeed have a clinically significant effect on some of
the hamartomas in TSC. It may be that the dose of metformin used in
this study is not adequate to produce a significant inhibitory effect in
the renal lesions. There is no published information to suggest an
optimal dose of metformin when the objective is to reduce tumour or
hamartoma size. The dose used in this study was chosen because it
was the dose that is used, shown to be effective, and tolerated when
treating type 2 diabetes patients which is the current main indication
for metformin use. Further studies using different dosing regimens
may well be justified.
The effect of metformin in reducing the volume of SEGAs in TSC
patients in this study is striking. SEGAs are another important cause
of morbidity, and occasional mortality, in TSC patients [25, 28]. They
are hamartomas that grow at the foramen of Monro and can cause
obstruction to flow of cerebrospinal fluid and consequent hydroceph-
alus. They occur in up to 30% of TSC patients [29]. Metformin has been
shown to have a beneficial effect in more aggressive brain tumours
such as high grade gliomas [30]. Metformin effectively crosses the
blood-brain barrier and is distributed in multiple brain regions after
oral dosing [31]. The apparent effect of metformin in reducing SEGA
volume in the patients in this study is clinically meaningful and is
potentially important for the future treatment of TSC patients. It is
certainly a finding that needs replication and further research. SEGAs
are known to grow in the first three decades of life and then become
more quiescent such that current screening recommendations sug-
gest screening only up to the age of 25 [32]. In a post-hoc analysis we
subdivided the patients in this study into those less than 30 years
and therefore at an age when SEGA growth would be most likely and
those greater than 30 years who might be less likely to have active
lesions. The effect of metformin on the SEGAs of those patients less
than 30 years was more marked than in the older patients.
There is emerging evidence from animal work that metformin
may have an anti-epileptic and anti-epileptogenic effect. Metformin
may have an anti-epileptic effect via a number of different pathways:
inhibition of MTOR, activation of AMPK and prevention of oxidative
damage induced by seizure activity. Metformin has been shown to
suppress seizures in some rodent models and Bruegeman et al. have
recently demonstrated that metformin significantly suppressed sei-
zure behaviour in a zebrafish PTZ-induced seizure model [33-35].
Metformin has not previously been studied in any clinical trial for
human seizures or epilepsy. Consequently, the reduction of seizure
activity seen in patients treated with metformin in this study is inter-
esting. However, our study data is undermined by the failure to
obtain seizure data in eight patients and we did not control for altera-
tions in other anti-epileptic drugs. Nevertheless, the findings are suf-
ficiently intriguing to justify further study of the possible anti-
epileptic effects of metformin in tuberous sclerosis complex in an
adequately powered clinical trial.
Everolimus and rapamycin are two mTOR inhibitors that have
been shown to be effective at both reducing hamartoma size andimproving refractory epilepsy in TSC [11, 36, 37]. However, these
agents have significant side-effects. The most common side-effects of
these agents are mouth ulceration and stomatitis but there is a risk of
immunosuppression and severe infection. Two deaths in the recently
reported EXIST-3 study were attributed to treatment [38]. Metformin
inhibits mTOR via a different mechanism than everolimus and rapa-
mycin and it has a significantly more benign side-effect profile. At the
dose used in this study, it does not appear to be as potent an mTOR
inhibitor as rapamycin or everolimus and does not have such a dra-
matic effect on the hamartomas associated with TSC. However, given
its better side-effect profile it may prove to be a more attractive
option for TSC patients who may benefit from long-term mTOR inhi-
bition to prevent the development of symptomatic SEGAs and to
improve their long-term epilepsy control. It is also possible that it
could be given in conjunction with other mTOR inhibitors possibly
having a synergistic effect and possibly allowing use of lower doses
of more toxic mTOR inhibitors and thus reducing the incidence of
severe side-effects. These questions need to be explored in future
research.
Metformin has the advantage of not interacting with the cyto-
chrome p450 system and therefore it is unlikely to interfere with the
metabolism of other mTOR inhibitors. For the same reason, and in
contrast to the other mTOR inhibitors everolimus and rapamycin, the
metabolism of metformin will not be disturbed by antiepileptic drugs
such as cannabidiol or carbamazepine that many TSC patients may be
taking [39].
The obvious strengths of this trial are that treatment was rando-
mised and that participants, families and carers, and investigators
were blind to treatment allocation and therefore outcomes were
assessed objectively and without bias. All the patients who started
treatment in the trial were assessed for the primary outcome and all
those who had SEGAs were assessed for SEGA growth at the end of
the trial. There are, however, limitations with this study. The trial
was small with just fifty-one participants. Although it was not possi-
ble to do a meaningful power calculation in this study because of a
complete lack of data to support any assumptions regarding effect
size, we had initially aimed to recruit 72 patients. Recruitment was
difficult for several reasons. Firstly, the trial took place at the same
time as industry-sponsored trials of the mTOR inhibitor everolimus
that were looking at the same population of patients. Secondly, the
trial required annual MRI scans of brain and kidney and these
required general anaesthesia in learning disability patients and
sometimes carers were reluctant to submit individuals for general
anaesthesia for a research study. Thirdly, the limited finance for the
study prevented extension of the study to multiple sites beyond
where the investigators worked. It is possible that the small numbers
in the study has precluded seeing a significant difference between
metformin and placebo with respect to angiomyolipoma growth but
there was certainly no evidence from this data to suggest metformin
was causing angiomyolipomas to shrink. It is more likely that greater
numbers in the study may have enabled us to see even more convinc-
ing effects of metformin on SEGA growth and on epilepsy control.
Consequently, we think there is a strong case for doing a larger study
looking at these two outcomes in particular.
Health related quality of life was one of the secondary outcomes
of this study. Unfortunately, the data for this outcome is incomplete
mainly due to the impossibility of obtaining quality of life scores in
learning disabled adult patients using the SF-36 but also due to the
incomplete return of questionnaires to the study team. Quality of life
scores were only obtained for 9 out of 12 (75%) children in the study
and 9 out of 39 (23%) adults. The paucity of data for this outcome cau-
tions against definitive conclusions in this area. The quality of life
data that was collected did not suggest that there was a meaningful
change during the course of the study in either group. The statisti-
cally significant difference in change of the SF-36 physical health
scores between the metformin and placebo groups is curious and
S. Amin et al. / EClinicalMedicine 32 (2021) 100715 11probably relates to the very low baseline score in the patients taking
placebo compared to the metformin patients.
As with all clinical trials there is a possible issue with respect to
external validity with this data. Sixty-eight per cent of the partici-
pants in this trial had learning disability compared with a rate of
approximately 50% seen in epidemiological studies of tuberous scle-
rosis complex patients. However, the increased representation of
learning disability patients in this trial may reflect the fact that more
severe renal disease is more common in learning disabled TSC
patients. [25] We should be aware, however, that the results from
this trial may not map directly onto a general population of TSC
patients.
One definite issue for the study is that seizure diary data was
available for just 73% of the patients with epilepsy. The major reason
for this was that some carers of individuals with learning disabilities
in residential care homes were unable to complete the daily seizure
diary due to short staffing issues. The results from this study suggest
that metformin may have had a beneficial effect on seizure control,
but the incompleteness of the dataset means that this result should
be treated with caution. However, it strengthens the need to look at
the effect of metformin on epilepsy in TSC in a larger trial in which
epilepsy control is a primary outcome.
Metformin was well tolerated by children and adults in this study.
Gastric upset is not uncommonly reported in diabetic patients. We
encountered only one patient who complained of gastric upset and
this settled quickly. This side effect was not commonly reported in
our study probably because we did not use high doses and we gradu-
ally built the dose up over 6 months. The possible side effect of lactic
acidosis with metformin use is still controversial. None of our
patients developed lactic acidosis. In addition, none of the patients
who were taking metformin developed hypoglycaemia. Metformin
increases the sensitivity to insulin rather than insulin level, thus
hypoglycaemia is not expected to occur due to metformin adminis-
tration [16].
Metformin is apparently safe and well tolerated in children and
adults with TSC when used in the doses used in this trial. Metformin
did not reduce AML size. Patients on metformin had a reduction in
SEGA volume compared with placebo, which was more marked in
younger (< 30 years of age) patients. Patients on metformin also
appeared to have fewer epileptic seizures, although seizure diary
data was complete for just 73% of patients. There may be a role for
metformin in slowing or reversing growth of life-threatening hamar-
tomas in TSC and for helping to control the frequency of epileptic
seizures. Further study is justified.Author contributions
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